Your browser doesn't support javascript.
loading
Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
Cicconi, P; Bongiovanni, M; Melzi, S; Tordato, F; d'Arminio Monforte, A; Bini, T.
Afiliação
  • Cicconi P; Institute of Infectious and Tropical Diseases, Luigi Sacco Hospital, via G.B. Grassi 74, 20157 Milan, Italy.
Int J Antimicrob Agents ; 24(3): 284-5, 2004 Sep.
Article em En | MEDLINE | ID: mdl-15325433
The use of tenofovir as part of a HAART regimen has been widely used in HIV-multi-experienced-patients because of its favourable resistance profile. Tenofovir is mainly eliminated by the kidneys and renal toxicity should be carefully monitored. We describe here the case of an HIV-infected patient, without a prior history of renal failure who developed nephrolithiasis and hydronephrosis after starting a tenofovir-containing HAART regimen.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenina / Cálculos Renais / Infecções por HIV / Fármacos Anti-HIV / Organofosfonatos / Hidronefrose Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2004 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenina / Cálculos Renais / Infecções por HIV / Fármacos Anti-HIV / Organofosfonatos / Hidronefrose Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2004 Tipo de documento: Article